PCI Biotech Holding ASA (PCIB.OL)
NOK 1.39
(-4.79%)
NOK 1.39
(-4.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 44.05 Million NOK | -30.61% |
| 2022 | 63.48 Million NOK | -53.31% |
| 2021 | 135.97 Million NOK | -34.98% |
| 2020 | 209.12 Million NOK | -25.85% |
| 2019 | 282.03 Million NOK | -21.01% |
| 2018 | 357.05 Million NOK | 511.02% |
| 2017 | 58.43 Million NOK | 160.9% |
| 2016 | 22.39 Million NOK | -60.29% |
| 2015 | 56.39 Million NOK | 176.71% |
| 2014 | 20.38 Million NOK | -61.35% |
| 2013 | 52.73 Million NOK | -32.56% |
| 2012 | 78.2 Million NOK | -21.93% |
| 2011 | 100.16 Million NOK | -12.55% |
| 2010 | 114.54 Million NOK | 175.82% |
| 2009 | 41.52 Million NOK | -23.91% |
| 2008 | 54.57 Million NOK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 37.41 Million NOK | 0.0% |
| 2024 Q1 | 37.41 Million NOK | -15.07% |
| 2023 Q1 | 57.61 Million NOK | -9.24% |
| 2023 Q3 | 44.05 Million NOK | -16.12% |
| 2023 Q2 | 52.51 Million NOK | -8.85% |
| 2023 FY | 44.05 Million NOK | -30.61% |
| 2023 Q4 | 44.05 Million NOK | 0.0% |
| 2022 Q2 | 93.24 Million NOK | -14.77% |
| 2022 Q4 | 63.48 Million NOK | -14.14% |
| 2022 Q3 | 73.93 Million NOK | -20.71% |
| 2022 Q1 | 109.4 Million NOK | -19.54% |
| 2022 FY | 63.48 Million NOK | -53.31% |
| 2021 Q2 | 171.88 Million NOK | -7.74% |
| 2021 Q1 | 186.31 Million NOK | -10.91% |
| 2021 Q4 | 135.97 Million NOK | -12.09% |
| 2021 Q3 | 154.68 Million NOK | -10.01% |
| 2021 FY | 135.97 Million NOK | -34.98% |
| 2020 Q4 | 209.12 Million NOK | -11.46% |
| 2020 Q1 | 280.92 Million NOK | -0.39% |
| 2020 Q2 | 257.19 Million NOK | -8.45% |
| 2020 Q3 | 236.19 Million NOK | -8.17% |
| 2020 FY | 209.12 Million NOK | -25.85% |
| 2019 Q1 | 340.42 Million NOK | -4.66% |
| 2019 Q2 | 321.72 Million NOK | -5.5% |
| 2019 Q3 | 308.3 Million NOK | -4.17% |
| 2019 Q4 | 282.03 Million NOK | -8.52% |
| 2019 FY | 282.03 Million NOK | -21.01% |
| 2018 Q2 | 37.87 Million NOK | -20.18% |
| 2018 Q1 | 47.44 Million NOK | -18.81% |
| 2018 Q4 | 357.05 Million NOK | 1046.54% |
| 2018 FY | 357.05 Million NOK | 511.02% |
| 2018 Q3 | 31.14 Million NOK | -17.77% |
| 2017 Q3 | 65.74 Million NOK | -7.77% |
| 2017 Q2 | 71.28 Million NOK | -9.82% |
| 2017 Q1 | 79.04 Million NOK | 252.93% |
| 2017 FY | 58.43 Million NOK | 160.9% |
| 2017 Q4 | 58.43 Million NOK | -11.11% |
| 2016 Q2 | 40.04 Million NOK | -16.23% |
| 2016 Q1 | 47.8 Million NOK | -15.23% |
| 2016 Q3 | 30.48 Million NOK | -23.89% |
| 2016 Q4 | 22.39 Million NOK | -26.52% |
| 2016 FY | 22.39 Million NOK | -60.29% |
| 2015 Q1 | 78 Million NOK | 282.7% |
| 2015 FY | 56.39 Million NOK | 176.71% |
| 2015 Q3 | 61.55 Million NOK | -11.97% |
| 2015 Q2 | 69.91 Million NOK | -10.37% |
| 2015 Q4 | 56.39 Million NOK | -8.37% |
| 2014 FY | 20.38 Million NOK | -61.35% |
| 2014 Q4 | 20.38 Million NOK | -25.35% |
| 2014 Q2 | 35.03 Million NOK | -18.6% |
| 2014 Q3 | 27.3 Million NOK | -22.07% |
| 2014 Q1 | 43.03 Million NOK | -18.39% |
| 2013 Q2 | 64.44 Million NOK | -9.77% |
| 2013 Q3 | 58.83 Million NOK | -8.7% |
| 2013 Q4 | 52.73 Million NOK | -10.37% |
| 2013 FY | 52.73 Million NOK | -32.56% |
| 2013 Q1 | 71.42 Million NOK | -8.67% |
| 2012 Q1 | 95.64 Million NOK | -4.51% |
| 2012 Q2 | 91.79 Million NOK | -4.03% |
| 2012 FY | 78.2 Million NOK | -21.93% |
| 2012 Q3 | 84.11 Million NOK | -8.36% |
| 2012 Q4 | 78.2 Million NOK | -7.03% |
| 2011 FY | 100.16 Million NOK | -12.55% |
| 2011 Q1 | 110.28 Million NOK | -3.71% |
| 2011 Q3 | 103.86 Million NOK | -2.3% |
| 2011 Q2 | 106.3 Million NOK | -3.61% |
| 2011 Q4 | 100.16 Million NOK | -3.56% |
| 2010 Q3 | 116.6 Million NOK | -0.59% |
| 2010 Q2 | 117.29 Million NOK | 0.0% |
| 2010 FY | 114.54 Million NOK | 175.82% |
| 2010 Q4 | 114.54 Million NOK | -1.77% |
| 2009 FY | 41.52 Million NOK | -23.91% |
| 2009 Q4 | 41.52 Million NOK | 0.0% |
| 2008 FY | 54.57 Million NOK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arctic Bioscience AS | 300.25 Million NOK | 85.329% |
| Aqua Bio Technology ASA | 34.42 Million NOK | -27.943% |
| ArcticZymes Technologies ASA | 339.32 Million NOK | 87.018% |
| BerGenBio ASA | 174.33 Million NOK | 74.733% |
| Hofseth BioCare ASA | 390.11 Million NOK | 88.709% |
| Thor Medical ASA | 330.83 Million NOK | 86.685% |
| Ultimovacs ASA | 349.03 Million NOK | 87.38% |